Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Cash Flows

v3.23.1
Consolidated Statements of Cash Flows - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Cash flows from operating activities:    
Net loss from ongoing operations $ (15,197,336) $ (29,889,045)
Adjustments to reconcile net loss to net cash used in operating activities:    
Accrued interest/dividends (3,024)
Accretion of debt discount 608,460
(Gain)/loss on sale of marketable securities 5,964 (39,597)
Unrealized (gain)/loss on marketable securities (2,958) 42,793
Gain on forgiveness of debt (180,258)
Stock based compensation:    
Option modification expense 15,036,051
Options issued to key employees 338,922
Options issued to non-employees 105,420 90,002
Warrants issued for services 84,851
Restricted stock units to non-employees 165,997
Change in assets and liabilities    
Prepaid expenses 540,560 (912,815)
Trade and other payables 1,686,595 (4,268,961)
Operating leases 1,917 (81)
Net cash used by operating activities (12,270,068) (19,516,475)
Cash flows from investing activities:    
Purchases of marketable securities (4,836,837) (13,403)
Proceeds from sale of marketable securities 11,750,000 18,483,176
Net cash received in business combination 1,380,852
Net cash provided by investing activities 6,913,163 19,850,625
Cash flows from financing activities    
Repayment of the line of credit – related party (3,062,444)
Net proceeds from borrowings 120,000
Net proceeds from note payable 1,826,137
Net proceeds from issuance of Common Stock 5,550,028
Net proceeds from the exercise of warrants for Common Stock 1,189,840
Net cash provided by financing activities 5,550,028 73,533
Net increase in cash and cash equivalents 193,123 407,683
Cash and cash equivalents at beginning of year 555,967 148,284
Cash and cash equivalents at end of year 749,090 555,967
Supplemental cash flow information    
Interest 13,322 271,800
Income Taxes
Supplemental Schedule of Non-Cash Financing and Investing Activities    
Operating lease right-of-use asset obtained in exchange for lease obligation 53,196 141,387
Investment in Oravax Medical, Inc. $ 1,500,000